<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="50595">single-walled carbon nanotube</z:chebi>-111In-labeled1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid -rituximab (<z:chebi fb="46" ids="50594">CNT</z:chebi>-([111In]DOTA)(rituximab) is a nanoconstruct with multiple copies of the 111In-labeled DOTA chelate and anti-CD20 monoclonal antibody (MAb) independently attached covalently to the <z:chebi fb="46" ids="50594">CNT</z:chebi>-sidewall and can be used for imaging lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (1) </plain></SENT>
<SENT sid="1" pm="."><plain>The CD20 antigen is a 35-kDa, nonglycosylated, cell-surface hydrophobic phosphoprotein expressed on <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant B cells (2-4) </plain></SENT>
<SENT sid="2" pm="."><plain>It is a transmembrane protein that acts as a calcium channel and plays an important role in cell cycle progression and differentiation of B cells </plain></SENT>
<SENT sid="3" pm="."><plain>CD20 is present on &gt;90% of B cells from blood and lymphoid organs </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> cells from &gt;90% of patients with B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) expressed this antigen </plain></SENT>
<SENT sid="5" pm="."><plain>When antibodies bind to this antigen, they may induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="6" pm="."><plain>Despite the presence of CD20 on <z:mpath ids='MPATH_458'>normal</z:mpath> B cells, it was proven to be an excellent <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> target for molecular targeting with antibodies for the management of NHL </plain></SENT>
<SENT sid="7" pm="."><plain>Radiolabeled MAbs have been developed for both diagnosis and therapy of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (2, 5, 6) </plain></SENT>
<SENT sid="8" pm="."><plain>Rituximab (unlabeled chimeric 2B8 MAb) was constructed and approved by the United States Food and Drug Administration for use in NHL therapy (7, 8) </plain></SENT>
<SENT sid="9" pm="."><plain>Later, ibritumomab (intact murine anti-CD20 MAb), was labeled with 111In or 90Y for NHL imaging and therapy (9, 10) </plain></SENT>
<SENT sid="10" pm="."><plain>One limitation of radiolabeled MAbs is that only a small number of chelating moieties can be attached to each MAb molecule before the targeting capability is compromised and further, only a fraction of these chelates actually contain radionuclide (11, 12) </plain></SENT>
<SENT sid="11" pm="."><plain>As part of the development of nanotechnology, <z:chebi fb="0" ids="50594">carbon nanotubes</z:chebi> (<z:chebi fb="46" ids="50594">CNTs</z:chebi>) (13-16) are essentially hexagonal networks of carbon atoms arranged like a layer of <z:chebi fb="150" ids="33418,36977">graphite</z:chebi> rolled into a cylinder </plain></SENT>
<SENT sid="12" pm="."><plain>There are <z:chebi fb="0" ids="50595">single-walled CNTs</z:chebi> (<z:chebi fb="0" ids="50595">SWNT</z:chebi>) with only a single layer and <z:chebi fb="0" ids="50596">multi-walled CNTs</z:chebi> (<z:chebi fb="0" ids="50596">MWNT</z:chebi>) with many layers </plain></SENT>
<SENT sid="13" pm="."><plain>Both <z:chebi fb="0" ids="50595">SWNT</z:chebi> and <z:chebi fb="0" ids="50596">MWNT</z:chebi> may possess lengths up to tens of micrometers and diameters between a few nanometers and hundreds of nanometers </plain></SENT>
<SENT sid="14" pm="."><plain>There are numerous potential applications of <z:chebi fb="46" ids="50594">CNTs</z:chebi> in medicine </plain></SENT>
<SENT sid="15" pm="."><plain>For example, the integration of <z:chebi fb="46" ids="50594">CNTs</z:chebi> and biomolecules provides a novel platform to deliver a therapeutic or diagnostic “payload” to a molecular target (1, 17-19) </plain></SENT>
<SENT sid="16" pm="."><plain>A major advantage of <z:chebi fb="0" ids="50595">SWNTs</z:chebi> is that <z:hpo ids='HP_0000001'>all</z:hpo> carbon atoms are surface atoms that provide many potential attachment sites for appending various ligands and an enormous aspect ratio permitting the attachment of multiple copies of different moieties (1) </plain></SENT>
<SENT sid="17" pm="."><plain>Although there are some concerns about the toxic potential of <z:chebi fb="46" ids="50594">CNTs</z:chebi> (20), soluble, nonaggregated, functionalized <z:chebi fb="46" ids="50594">CNTs</z:chebi> appear to be nontoxic to the biological system (21, 22) </plain></SENT>
<SENT sid="18" pm="."><plain>McDevitt et al </plain></SENT>
<SENT sid="19" pm="."><plain>(1) first reported the synthesis of a <z:chebi fb="0" ids="50595">single-walled CNT</z:chebi>-([111In]DOTA)(rituximab) construct appended with multiple copies of DOTA chelate and antibodies to specifically target the CD20 <z:chebi fb="0" ids="53000">epitope</z:chebi> on human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
</text></document>